Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and DDI Study of Mezigdomide with Rifampin, Itraconazole, Digoxin, and Rosuvastatin
NCT05389722Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of mezigdomide in multiple myeloma (MM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 2 months, Time of maximum observed plasma concentration up to 2 months and 1 more. Started Jun 2022; status: completed.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05389722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389722.